Previously it has been shown that when HER2 negative gastric cancers are revaluated with either repeat endoscopic biopsy, or repeat sampling from metastatic or recurrence sites, in 8.7% and 5.7% respectively tumours were re-classified as HER2 positive [35]. Here, ERBB2 is linked to neoplasm.